{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:03:01Z","timestamp":1793138581022,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40120-025-00842-7","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:40:29Z","timestamp":1762162829000},"page":"41-60","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Caregiver-reported Patient Experiences with Duchenne Muscular Dystrophy: Qualitative In-trial Interviews 1\u00a0Year After Delandistrogene Moxeparvovec in the Pivotal EMBARK Trial"],"prefix":"10.1007","volume":"15","author":[{"given":"Ivana","family":"Audhya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alise B.","family":"Nacson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Gooch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonita","family":"Basnyat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Slota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire J.","family":"Lansdall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teofil","family":"Ciobanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravindhan","family":"Veerapandiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"842_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","volume":"31","author":"JR Mendell","year":"2025","unstructured":"Mendell JR, Muntoni F, McDonald CM, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2025;31:332\u201341. https:\/\/doi.org\/10.1038\/s41591-024-03304-z.","journal-title":"Nat Med"},{"issue":"1","key":"842_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13. https:\/\/doi.org\/10.1038\/s41572-021-00248-3.","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"842_CR3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s41573-023-00775-6","volume":"22","author":"TC Roberts","year":"2023","unstructured":"Roberts TC, Wood MJA, Davies KE. Therapeutic approaches for Duchenne muscular dystrophy. Nat Rev Drug Discov. 2023;22(11):917\u201334. https:\/\/doi.org\/10.1038\/s41573-023-00775-6.","journal-title":"Nat Rev Drug Discov"},{"key":"842_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8396429","volume":"2020","author":"S Han","year":"2020","unstructured":"Han S, Xu H, Zheng J, et al. Population-wide Duchenne muscular dystrophy carrier detection by CK and molecular testing. Biomed Res Int. 2020;2020:8396429. https:\/\/doi.org\/10.1155\/2020\/8396429.","journal-title":"Biomed Res Int"},{"issue":"2","key":"842_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/dmcn.14248","volume":"62","author":"B El-Aloul","year":"2020","unstructured":"El-Aloul B, Speechley KN, Wei Y, Wilk P, Campbell C. Fatigue in young people with Duchenne muscular dystrophy. Dev Med Child Neurol. 2020;62(2):245\u201351. https:\/\/doi.org\/10.1111\/dmcn.14248.","journal-title":"Dev Med Child Neurol"},{"key":"842_CR6","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejpn.2021.11.004","volume":"36","author":"P Hafner","year":"2022","unstructured":"Hafner P, Schmidt S, Schadelin S, et al. Implementation of motor function measure score percentile curves - predicting motor function loss in Duchenne muscular dystrophy. Eur J Paediatr Neurol. 2022;36:78\u201383. https:\/\/doi.org\/10.1016\/j.ejpn.2021.11.004.","journal-title":"Eur J Paediatr Neurol"},{"key":"842_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ejpn.2023.10.002","volume":"47","author":"F Ortiz-Corredor","year":"2023","unstructured":"Ortiz-Corredor F, Sandoval-Salcedo A, Castellar-Leones S, Soto-Pena D, Ruiz-Ospina E, Suarez-Obando F. Trajectories of motor function in children with Duchenne muscular dystrophy: a longitudinal study on a Colombian population. Eur J Paediatr Neurol. 2023;47:105\u20139. https:\/\/doi.org\/10.1016\/j.ejpn.2023.10.002.","journal-title":"Eur J Paediatr Neurol"},{"issue":"23","key":"842_CR8","doi-asserted-by":"publisher","first-page":"e2304","DOI":"10.1212\/wnl.0000000000012910","volume":"97","author":"J Broomfield","year":"2021","unstructured":"Broomfield J, Hill M, Guglieri M, Crowther M, Abrams K. Life expectancy in Duchenne muscular dystrophy: reproduced individual patient data meta-analysis. Neurology. 2021;97(23):e2304\u201314. https:\/\/doi.org\/10.1212\/wnl.0000000000012910.","journal-title":"Neurology"},{"key":"842_CR9","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.2147\/jmdh.S458181","volume":"17","author":"R Fischer","year":"2024","unstructured":"Fischer R, Furlong P, Kennedy A, et al. Healthcare stakeholder perspectives on a value assessment approach for Duchenne muscular dystrophy therapies. J Multidiscip Healthc. 2024;17:4199\u2013212. https:\/\/doi.org\/10.2147\/jmdh.S458181.","journal-title":"J Multidiscip Healthc"},{"key":"842_CR10","unstructured":"Givinostat PI. Highlights of prescribing information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217865Orig1s000lbl.pdf. Accessed 17 Feb 2025"},{"key":"842_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2025.100787","volume":"102","author":"AF Anjum","year":"2025","unstructured":"Anjum AF, Anjum MB, Rehman RU. Unleashing the potential of Givinostat: a novel therapy for Duchenne muscular dystrophy. Curr Ther Res Clin Exp. 2025;102:100787. https:\/\/doi.org\/10.1016\/j.curtheres.2025.100787.","journal-title":"Curr Ther Res Clin Exp"},{"issue":"1","key":"842_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s41687-023-00669-6","volume":"7","author":"V Brown","year":"2023","unstructured":"Brown V, Merikle E, Johnston K, Gooch K, Audhya I, Lowes L. A qualitative study to understand the Duchenne muscular dystrophy experience from the parent\/patient perspective. J Patient Rep Outcomes. 2023;7(1):129. https:\/\/doi.org\/10.1186\/s41687-023-00669-6.","journal-title":"J Patient Rep Outcomes"},{"key":"842_CR13","unstructured":"Sarepta Therapeutics. ELEVIDYS (delandistrogene moxeparvovec-rokl) suspension, for intravenous infusion. 2024. https:\/\/www.fda.gov\/media\/169679\/download?attachment. Accessed 18 Dec 2024"},{"issue":"1","key":"842_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41598-024-84077-w","volume":"15","author":"RA Potter","year":"2025","unstructured":"Potter RA, Moeller IH, Khan S, et al. Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy. Sci Rep. 2025;15(1):4. https:\/\/doi.org\/10.1038\/s41598-024-84077-w.","journal-title":"Sci Rep"},{"issue":"1","key":"842_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40120-024-00685-8","volume":"14","author":"CM McDonald","year":"2025","unstructured":"McDonald CM, Elkins JS, Dharmarajan S, et al. Caregiver global impression observations from EMBARK: a phase 3 study evaluating delandistrogene moxeparvovec in ambulatory patients with Duchenne muscular dystrophy. Neurol Ther. 2025;14(1):211\u201325. https:\/\/doi.org\/10.1007\/s40120-024-00685-8.","journal-title":"Neurol Ther"},{"key":"842_CR16","unstructured":"Mattina C. EMBARK Data Show Continued Improvements With DMD Gene Therapy. 2025. https:\/\/www.ajmc.com\/view\/embark-data-show-continued-improvements-with-dmd-gene-therapy. Accessed 10 June 2025"},{"key":"842_CR17","unstructured":"McNulty R. EMBARK 2: Delandistrogene Moxeparvovec Shows Sustained Benefits in DMD. 2025. https:\/\/www.ajmc.com\/view\/embark-2-delandistrogene-moxeparvovec-shows-sustained-benefits-in-dmd. 09 July 2025"},{"key":"842_CR18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203455","author":"F Muntoni","year":"2023","unstructured":"Muntoni F, Mercuri E, Schmidt US, et al. EMBARK, a phase 3 trial evaluating safety and efficacy of delandistrogene moxeparvovec (SRP- 9001) in Duchenne muscular dystrophy (DMD): study design and baseline characteristics (P5\u20138.012). Neurology. 2023. https:\/\/doi.org\/10.1212\/WNL.0000000000203455.","journal-title":"Neurology"},{"issue":"1","key":"842_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12955-021-01813-w","volume":"19","author":"H Staunton","year":"2021","unstructured":"Staunton H, Trennery C, Arbuckle R, et al. Development of a clinical global impression of change (CGI-C) and a caregiver global impression of change (CaGI-C) measures for ambulant individuals with Duchenne muscular dystrophy. Health Qual Life Outcomes. 2021;19(1):184. https:\/\/doi.org\/10.1186\/s12955-021-01813-w.","journal-title":"Health Qual Life Outcomes"},{"issue":"2","key":"842_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa.","journal-title":"Qual Res Psychol"},{"issue":"4","key":"842_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1023\/a:1020909529486","volume":"36","author":"H Boeije","year":"2002","unstructured":"Boeije H. A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quant. 2002;36(4):391\u2013409. https:\/\/doi.org\/10.1023\/a:1020909529486.","journal-title":"Qual Quant"},{"key":"842_CR22","unstructured":"Food and Drug Administration (FDA). Patient-focused drug development: methods to identify what is important to patients. 2022. https:\/\/www.fda.gov\/media\/131230\/download. Accessed 14 Jan 2025"},{"issue":"5","key":"842_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40271-022-00574-y","volume":"15","author":"NL Crossnohere","year":"2022","unstructured":"Crossnohere NL, Fischer R, Vroom E, Furlong P, Bridges JFP. A comparison of caregiver and patient preferences for treating Duchenne muscular dystrophy. Patient. 2022;15(5):577\u201388. https:\/\/doi.org\/10.1007\/s40271-022-00574-y.","journal-title":"Patient"},{"issue":"9","key":"842_CR24","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1007\/s11136-018-1891-7","volume":"27","author":"IL Hollin","year":"2018","unstructured":"Hollin IL, Peay H, Fischer R, Janssen EM, Bridges JFP. Engaging patients and caregivers in prioritizing symptoms impacting quality of life for Duchenne and Becker muscular dystrophy. Qual Life Res. 2018;27(9):2261\u201373. https:\/\/doi.org\/10.1007\/s11136-018-1891-7.","journal-title":"Qual Life Res"},{"issue":"1","key":"842_CR25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/mus.28102","volume":"70","author":"S Rosero","year":"2024","unstructured":"Rosero S, Weinstein J, Seabury J, et al. Patient- and caregiver-reported impact of symptoms in Duchenne muscular dystrophy. Muscle Nerve. 2024;70(1):120\u20139. https:\/\/doi.org\/10.1002\/mus.28102.","journal-title":"Muscle Nerve"},{"issue":"1","key":"842_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13023-023-02674-w","volume":"18","author":"CE Schwartz","year":"2023","unstructured":"Schwartz CE, Jackson S, Valentine J, et al. Toward patient-centered treatment goals for duchenne muscular dystrophy: insights from the \u201cYour Voice\u201d study. Orphanet J Rare Dis. 2023;18(1):90. https:\/\/doi.org\/10.1186\/s13023-023-02674-w.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"842_CR27","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1016\/j.clinthera.2017.09.013","volume":"39","author":"L Anthony","year":"2017","unstructured":"Anthony L, Ervin C, Lapuerta P, et al. Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of Telotristat ethyl. Clin Ther. 2017;39(11):2158\u201368. https:\/\/doi.org\/10.1016\/j.clinthera.2017.09.013.","journal-title":"Clin Ther"},{"issue":"11","key":"842_CR28","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1016\/j.clinthera.2019.09.003","volume":"41","author":"C Ervin","year":"2019","unstructured":"Ervin C, Joish VN, Evans E, et al. Insights into patients\u2019 experience with type 1 diabetes: exit interviews from phase iii studies of Sotagliflozin. Clin Ther. 2019;41(11):2219-30.e6. https:\/\/doi.org\/10.1016\/j.clinthera.2019.09.003.","journal-title":"Clin Ther"},{"issue":"1","key":"842_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40257-022-00733-9","volume":"24","author":"JC Browning","year":"2023","unstructured":"Browning JC, Cartwright M, Thorla I Jr, Martin SA, Olayinka-Amao O, Maeda-Chubachi T. A patient-centered perspective of molluscum contagiosum as reported by B-SIMPLE4 clinical trial patients and caregivers: global impression of change and exit interview substudy results. Am J Clin Dermatol. 2023;24(1):119\u201333. https:\/\/doi.org\/10.1007\/s40257-022-00733-9.","journal-title":"Am J Clin Dermatol"},{"key":"842_CR30","doi-asserted-by":"crossref","unstructured":"DiBenedetti DB, Brown T, Romano C, Ervin C, Lewis S, Fehnel SE. RTI Press Occasional Papers. Conducting patient interviews within a clinical trial setting. RTI Press \u00a9 2018 Research Triangle Institute. All rights reserved.; 2018","DOI":"10.3768\/rtipress.2018.op.0054.1808"},{"issue":"1","key":"842_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s41687-021-00386-y","volume":"5","author":"CE Schwartz","year":"2021","unstructured":"Schwartz CE, Stark RB, Audhya IF, Gooch KL. Characterizing the quality-of-life impact of Duchenne muscular dystrophy on caregivers: a case-control investigation. J Patient Rep Outcomes. 2021;5(1):124. https:\/\/doi.org\/10.1186\/s41687-021-00386-y.","journal-title":"J Patient Rep Outcomes"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00842-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00842-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00842-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T13:51:52Z","timestamp":1768398712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00842-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["842"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00842-7","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ivana Audhya, Alise B. Nacson, and Katherine Gooch are employees of Sarepta Therapeutics, Inc., and may hold shares and\/or stock options in the company. Bonita Basnyat, Christina Slota, and Susan Martinare full-time employees of RTI-HS, a subsidiary of RTI International, an independent nonprofit research organization, which was retained by Sarepta Therapeutics, Inc., to conduct the research that is the subject of this manuscript; their compensation is unconnected to the studies on which they work. Alex Murphy, Claire J. Lansdall, and Teofil Ciobanu are full-time employees and minor shareholders of F. Hoffmann-La Roche AG. Andres Nascimento has received fees from AveXis, Biogen, and F. Hoffmann-La Roche, Ltd. Aravindhan Veerapandiyan has a consultancy\/advisory role with AMO Pharma, AveXis, Biogen, Edgewise Therapeutics, FibroGen, Novartis, Pfizer, PTC Therapeutics, Sarepta Therapeutics, UCB Pharma, Catalyst, and Scholar Rock; has received research funding from AMO Pharma, Capricor Therapeutics, Edgewise Therapeutics, FibroGen, the Muscular Dystrophy Association, Novartis, Parent Project Muscular Dystrophy, Pfizer, RegenxBio, and Sarepta Therapeutics; and has other relationship(s) with MedLink Neurology for editorial services.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The main EMBARK trial protocol, including the optional, qualitative in-trial interview substudy, was approved by an institutional review board and ethics committee at each site. The full list of institutional review boards and ethics committees has been published [\n                      \n                      ], and the trial was conducted in accordance with both the Declaration of Helsinki and Good Clinical Practice guidelines [\n                      \n                      ]. All eligible caregivers provided informed consent to participate in EMBARK [\n                      \n                      ] and additional consent to participate in the interview substudy and be audio-recorded. Interview participants were aware that their responses may be collated and published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}